TY - JOUR
T1 - G2C4 targeting antisense oligonucleotides potently mitigate TDP-43 dysfunction in human C9orf72 ALS/FTD induced pluripotent stem cell derived neurons
AU - Rothstein, Jeffrey D.
AU - Baskerville, Victoria
AU - Rapuri, Sampath
AU - Mehlhop, Emma
AU - Jafar-Nejad, Paymaan
AU - Rigo, Frank
AU - Bennett, Frank
AU - Mizielinska, Sarah
AU - Isaacs, Adrian
AU - Coyne, Alyssa N.
N1 - Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2024/6
Y1 - 2024/6
N2 - The G4C2 repeat expansion in the C9orf72 gene is the most common genetic cause of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Many studies suggest that dipeptide repeat proteins produced from this repeat are toxic, yet, the contribution of repeat RNA toxicity is under investigated and even less is known regarding the pathogenicity of antisense repeat RNA. Recently, two clinical trials targeting G4C2 (sense) repeat RNA via antisense oligonucleotide failed despite a robust decrease in sense-encoded dipeptide repeat proteins demonstrating target engagement. Here, in this brief report, we show that G2C4 antisense, but not G4C2 sense, repeat RNA is sufficient to induce TDP-43 dysfunction in induced pluripotent stem cell (iPSC) derived neurons (iPSNs). Unexpectedly, only G2C4, but not G4C2 sense strand targeting, ASOs mitigate deficits in TDP-43 function in authentic C9orf72 ALS/FTD patient iPSNs. Collectively, our data suggest that the G2C4 antisense repeat RNA may be an important therapeutic target and provide insights into a possible explanation for the recent G4C2 ASO clinical trial failure.
AB - The G4C2 repeat expansion in the C9orf72 gene is the most common genetic cause of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Many studies suggest that dipeptide repeat proteins produced from this repeat are toxic, yet, the contribution of repeat RNA toxicity is under investigated and even less is known regarding the pathogenicity of antisense repeat RNA. Recently, two clinical trials targeting G4C2 (sense) repeat RNA via antisense oligonucleotide failed despite a robust decrease in sense-encoded dipeptide repeat proteins demonstrating target engagement. Here, in this brief report, we show that G2C4 antisense, but not G4C2 sense, repeat RNA is sufficient to induce TDP-43 dysfunction in induced pluripotent stem cell (iPSC) derived neurons (iPSNs). Unexpectedly, only G2C4, but not G4C2 sense strand targeting, ASOs mitigate deficits in TDP-43 function in authentic C9orf72 ALS/FTD patient iPSNs. Collectively, our data suggest that the G2C4 antisense repeat RNA may be an important therapeutic target and provide insights into a possible explanation for the recent G4C2 ASO clinical trial failure.
KW - ALS
KW - Antisense oligonucleotides
KW - C9orf72
KW - Induced pluripotent stem cell derived neurons
KW - Repeat RNA
KW - TDP-43
UR - http://www.scopus.com/inward/record.url?scp=85178199517&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85178199517&partnerID=8YFLogxK
U2 - 10.1007/s00401-023-02652-3
DO - 10.1007/s00401-023-02652-3
M3 - Article
C2 - 38019311
AN - SCOPUS:85178199517
SN - 0001-6322
VL - 147
JO - Acta neuropathologica
JF - Acta neuropathologica
IS - 1
M1 - 1
ER -